News | January 04, 2022
Domestic and emerging markets will drive pharma growth: ICRA
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
During H1 FY2022, the revenues and operating profit margin (OPM) for ICRA sample set showed sharp improvement aided by volume uptick in Covid-19 and allied tests and also demand traction for non-Covid tests
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Adjusted PAT declined 18.8% YoY
Subscribe To Our Newsletter & Stay Updated
